The Association Between Antihypertensive Drug Use and Hospitalization for Pneumonia in the General Population: A Case-Crossover Study Using the National Health Insurance Database of Korea

Dougho Park,1 Jae-Hyun Yun,2 Sungyoun Chun,2 Byung-Mo Oh,2,4,5 and Hyoung Seop Kim6

1 Department of Rehabilitation Medicine, Pohang Stroke and Spine Hospital, Pohang, Korea
2 Department of Rehabilitation Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
3 Research and Analysis Team, National Health Insurance Service Ilsan Hospital, Goyang, Korea
4 National Traffic Injury Rehabilitation Hospital, Yangpyeong, Korea
5 Institute on Aging, Seoul National University, Seoul, Korea
6 Department of Physical Medicine and Rehabilitation, National Health Insurance Service Ilsan Hospital, Goyang, Korea

ABSTRACT

Background: Previous studies have reported an association between pneumonia risk and the use of certain drugs. We investigated the relationship between antihypertensive drugs and pneumonia in the general population.

Methods: This case-crossover study utilized the nationwide data of South Korea. We included participants who were hospitalized for pneumonia. A single case period was defined as 30 days before pneumonia onset, and two control periods were established (90–120 and 150–180 days before pneumonia onset). Further, we performed sensitivity and subgroup analyses (according to the presence of diabetes mellitus, documented disability, and whether participants were aged ≥70 years). We used conditional logistic regression models adjusted for covariates, such as angiotensin-converting-enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), other antihypertensives, statins, antipsychotics, benzodiazepine, and the number of outpatient visits.

Results: In total, 15,463 subjects were included in this study. ACE inhibitors (adjusted odds ratio [aOR], 0.660; 95% confidence interval [CI], 0.558–0.781), ARBs (aOR, 0.702; 95% CI, 0.640–0.770), and other antihypertensive drugs (aOR, 0.737; 95% CI, 0.665–0.816) were significantly associated with reduced pneumonia risk. Subgroup analyses according to the presence of diabetes mellitus, documented disability, and whether participants were aged ≥70 years consistently showed the association of antihypertensives with a reduced risk of hospitalization for pneumonia.

Conclusion: All antihypertensive drug types were related to a lower risk of hospitalization for pneumonia in the general population. Our results implied that frequent medical service usage and protective immunity were primarily related to a reduced risk of pneumonia in the general population of South Korea.
INTRODUCTION

Pneumonia is one of the most significant causes of mortality and morbidity worldwide. In South Korea, pneumonia ranked as the third most common cause of death in 2020. With an aging population, pneumonia continues to be a significant burden for the public healthcare system. In addition, since pneumonia can be fatal in the elderly, interest in its prevention and management has been continuous.

Previous studies have reported the incidence of pneumonia in relation to drug use. Some have shown that certain frequently prescribed drugs, such as proton pump inhibitors and antipsychotics, increase pneumonia risk. However, some previous studies identifying the relationship between antihypertensive drug use and pneumonia prevention have shown inconsistent results.

A previous study using a nationwide database in South Korea reported that angiotensin receptor blocker (ARB) use is associated with reduced hospitalization for pneumonia in patients with stroke. Our study attempted to investigate the relationship between antihypertensive drug use and the incidence of pneumonia in the general population. As a secondary analysis, we attempted to validate the drug–disease relationship identified in the previous study through the subgroup analysis of a more diverse population.

METHODS

Study design, data source, and participants
This study used a case-crossover study design to assess the association of the usage and types of antihypertensive drugs with the incidence of pneumonia while minimizing the confounding factors derived from demographic characteristics. This study was performed using data from the Korea National Health Insurance Service–National Sample Cohort (NHIS-NSC) database, which includes 2.2% of the total eligible Korean population from 2002 to 2015. The database contains individual medical information, such as diagnosis, prescribed medications, and hospitalization history, without personal identification. The diagnoses recorded in this cohort database were based on the International Classification of Diseases, 10th Revision (ICD-10). We extracted the data of those diagnosed with and hospitalized for pneumonia. All the enrolled participants in this study had a pneumonia event (cases), and each case served as its own control.

Variables included in this study
The primary endpoint of this study was hospitalization for pneumonia, which was defined as ICD-10 codes J12–18. We included the index date of the first-onset pneumonia from 2002 to 2015 to account for recurrent pneumonia.

The antihypertensive drug types were divided into 3 subgroups: angiotensin-converting-enzyme (ACE) inhibitors, ARBs, and other antihypertensive drugs. Patients with combination drugs including ACE inhibitors were categorized into the ACE inhibitor subgroup. Similarly, patients with combination drugs including ARBs were categorized into the ARB subgroup.
Statistical analysis
Categorical variables were expressed as frequencies and proportions. Our primary analysis was the comparison of each individual’s drug exposure period (30 days before the incidence of pneumonia, which was defined as the case period) to two control periods, each lasting 30 days (90–120 and 150–180 days before pneumonia onset) (Fig. 1). For the subgroup analyses, comparison were made according to exposure to other medications, such as statins, antipsychotics, and benzodiazepine, as well as by the number of outpatient clinic visits. We performed further subgroup analyses according to the presence of diabetes mellitus, documented disability, and whether the participants were aged ≥ 70 years. Finally, to verify the robustness of the primary results, we performed sensitivity analyses by modifying the case and control periods (Fig. 2). To adjust for confounding factors, the participants’ characteristics were included in the analyses. The entire medication list utilized in this study is available in Supplementary Data 1. Conditional logistic regression analysis was performed to determine the association between drug usage and pneumonia risk. For each model, we adjusted determinants such as ACE inhibitors, ARBs, other antihypertensives, statins, antipsychotics, benzodiazepine, and the number of outpatient visits. All statistical analyses were performed using the SAS system for Windows (SAS Institute Inc., Cary, NC, USA).

Ethics statement
This study protocol was reviewed and approved by the Institutional Review Board of National Health Insurance Service Ilsan Hospital (approval number: NHIS-2019-01-034). No informed consent was required from patients due to the nature of public data from NHIS.

Fig. 1. The case-crossover study design. Case period was defined as a 30-day window before the index date of new-onset pneumonia. Two control periods were each defined as a 30-day window in a 30-day interval. A 60-day washout period was set between the end of the last control period and the start of the case period.

Fig. 2. The sensitivity test design. The case and two control periods were changed from 30 to 45 or 60 days.
RESULTS

Baseline characteristics
Of 15,463 patients included in the final cohort, 7,383 (47.8%) were male, 10,284 (66.5%) were aged ≥ 70 years, 4,470 (28.9%) had diabetes mellitus, and 3,899 (38.4%) had a disability (Table 1). According to medicine usage, 1,183 (7.7%), 5,030 (32.5%), and 3,647 (23.6%) received ACE inhibitors, ARBs, and other antihypertensive drugs, respectively (Supplementary Table 1).

Risk of hospitalization for pneumonia
The use of ACE inhibitors (adjusted odds ratio [aOR], 0.660; 95% confidence interval [CI], 0.558–0.781), ARBs (aOR, 0.702; 95% CI, 0.640–0.770), and other antihypertensive drugs (aOR, 0.737; 95% CI, 0.665–0.816) were significantly associated with a reduced risk of pneumonia (Table 2). The sensitivity analyses revealed similar results (Supplementary Table 2).

In the subgroup analyses, the use of antihypertensive drugs significantly reduced the incidence of pneumonia regardless of the presence of diabetes mellitus or disability and whether the participants were aged ≥ 70 years (Table 3).

Among other determinants in the logistic regression models, antipsychotics significantly increased the risk of pneumonia (aOR, 1.346; 95% CI, 1.160–1.562). On the other hand, more frequent outpatient visits significantly decreased the risk of hospitalization for pneumonia.

### Table 1. Baseline characteristics

| Variables       | Values                  |
|-----------------|-------------------------|
| Total           | 15,463                  |
| Age group, yr   |                         |
| < 60            | 2,159 (14.0)            |
| 60–69           | 3,020 (19.5)            |
| 70–79           | 5,680 (36.7)            |
| ≥ 80            | 4,604 (29.8)            |
| Male            | 7,383 (47.8)            |
| Diabetes        | 4,470 (28.9)            |
| Disability degreea
| None            | 11,564 (74.8)           |
| Mild (grades 3–6) | 2,574 (16.7)           |
| Severe (grades 1–2) | 1,325 (21.8)       |
| Type of disabilitya
| None            | 11,564 (74.8)           |
| Physical disability | 1,504 (9.7)             |
| Brain lesion    | 998 (6.5)               |
| Visual disturbance | 348 (2.3)               |
| Hearing impairment | 488 (3.2)               |
| Others          | 562 (3.6)               |

Values are presented as number (%).

aData documented national disability registration.

### Table 2. Association between antihypertensive use and pneumonia risk

| Type of antihypertensive | Crude OR (95% CI) | Adjusted ORa (95% CI) |
|--------------------------|-------------------|-----------------------|
| ACE inhibitors           | 0.529 (0.453–0.618) | 0.660 (0.558–0.781)   |
| ARBs                     | 0.542 (0.499–0.589) | 0.702 (0.640–0.770)   |
| Others                   | 0.542 (0.499–0.589) | 0.737 (0.665–0.816)   |

CI = confidence interval, OR = odds ratio, ACE = angiotensin-converting enzyme, ARB = angiotensin receptor blocker.
aAdjusted for ACE inhibitors, ARBs, other antihypertensives, statins, antipsychotics, benzodiazepine, and the number of outpatient visits.
(aOR, 0.884; 95% CI, 0.878–0.891) and consistently decreased this risk in all subgroups. Odds ratios for other determinants and their sensitivity analyses results are shown in Supplementary Tables 3 and 4, respectively.

**DISCUSSION**

This was the first study to identify the association between antihypertensive drug usage and pneumonia prevention in the general population, using data from the Korean NHIS-NSC database. This study demonstrated that antihypertensive drug usage was related to a lower risk of hospitalization for pneumonia in the general population of South Korea. The results were consistent regardless of the type of antihypertensive drug used, the presence of diabetes mellitus or disability, or old age.

The preventive effects of ACE inhibitors or ARBs on the incidence of pneumonia are not consistent in previous studies.\textsuperscript{14,15} Our results confirmed that these drugs lowered the risk of pneumonia. Several mechanisms may explain these results. The findings of previous studies, including clinical trials, suggest that renin-angiotensin system (RAS) blockers—ACE inhibitors and ARBs—may reduce the risk of pneumonia or show a protective effect on the pulmonary function of specific populations, including older adults; or patients with stroke, neurodegenerative diseases, or chronic obstructive pulmonary diseases; and Asians.\textsuperscript{16-18} ACE inhibitors work by downregulating intrarenal RAS activation.\textsuperscript{19,20} Its main mechanism is to disturb the conversion of angiotensin I to angiotensin II. Dry cough, its major side effect, is attributed to the inhibitory mechanism of bradykinin and substance P degradation.\textsuperscript{21,22} The swallowing reflex, which may be regulated by substance p, is an important defensive mechanism preventing aspiration of oropharyngeal contents into the respiratory system.\textsuperscript{23,24} Further, as a complementary action, increased bradykinin and substance P levels can prevent asymptomatic aspiration and improve the coughing reflex.\textsuperscript{25,26} Thus, ACE inhibitors may be implicated in the stimulation of the swallowing reflex. Lastly, angiotensin II promotes cellular
immune response by activating lymphocytes in animals and humans. Thus, ACE inhibitors are tasked to reduce the risk of pneumonia and other extrapulmonary inflammations.

In contrast, several studies show no association between either ACE inhibitors or ARBs and the risk of pneumonia. A case-crossover study using data from the Taiwan Longitudinal Health Insurance database found that neither the use nor cumulative dose of ACE inhibitors or ARBs are associated with the risk of pneumonia among the general population of Taiwan.

This discrepancy may be due to various outcome definitions, racial differences, geographic and climate factors, or specific healthcare systems in each country studied. Our outcome definition, particularly that of pneumonia hospitalization, did not include all types of pneumonia. In a study on patients with stroke, ARB use is associated with reduced pneumonia hospitalization. Therefore, the difference in the target group may have contributed to the difference in the results.

We confirmed that other antihypertensives—other than ACE inhibitors and ARBs—also reduced the risk of pneumonia in the general population. The relationship between the use of other antihypertensives and the risk of pneumonia was rarely studied, and the mechanism of reduced pneumonia incidence due to these medications has also not been elucidated. We inferred that these results eventually determined the risk of pneumonia according to medical use and accessibility. That is, the higher the number of outpatient clinic visits, the more likely the receipt of medical care, and thus the lower the risk of pneumonia. Our logistic regression models consistently showed that frequent outpatient clinic visits lowered the risk of pneumonia regardless of the subgroup. As such, after being diagnosed with hypertension, patients must visit medical facilities more regularly to potentially lower their risk of pneumonia, allowing for the early detection and management of respiratory symptoms or administration of influenza and pneumococcal vaccines.

Furthermore, we can infer that the different results between patients with stroke and the general population are attributed to the various mechanisms of pneumonia development. In the general population, community-acquired pneumonia is common. In stroke patients, the estimated proportion of aspiration or hospital-acquired pneumonia cases is relatively high. Community- and hospital-acquired pneumonia have different main pathogens. Pathogens of community-acquired pneumonia, such as Streptococcus pneumoniae or Haemophilus influenza, are highly affected by vaccination and herd immunity. Therefore, a lowered risk of pneumonia in the general population may result from an immunity preventive effect on a main pathogen rather than the impact of a specific antihypertensive drug.

In addition, we included the subgroup analyses to illuminate the effect of the variables on various groups. Older adults with medical comorbidities had an increased incidence of community- and hospital-acquired pneumonia. In older adults and people with disabilities, swallowing dysfunction is a risk factors for pneumonia. Previous studies have suggested that the swallowing function significantly changes with age due to decreased oropharyngeal skeletal muscle strength and reduced peristalsis, which requires multiple swallowing. Diabetes mellitus is a risk factor for pneumonia hospitalization and is associated with other infectious diseases. Our results confirmed that antihypertensive drugs were universally effective in preventing pneumonia regardless of the subgroup.
Finally, we simultaneously investigated other medications as covariates to determine their effects on pneumonia hospitalization. Antipsychotics showed an increased risk of pneumonia hospitalization in the total patient group. Previous studies have also suggested an association between antipsychotics and pneumonia risk.\textsuperscript{44,45} These findings are primarily explained by dysphagia and secretion; antipsychotics can promote oropharyngeal dysphagia, which may be associated with an extrapyramidal adverse effect or a related anticholinergic reaction.\textsuperscript{46}

This study had several limitations. First, we included pneumonia cases that required hospitalization. Therefore, this study excluded some atypical or community-acquired pneumonia cases that can be treated in an outpatient clinic. Second, given the observational feature of this study design, we cannot suggest a precise mechanism to explain the association between antihypertensive use and pneumonia prevention. Third, this study design cannot eliminate confounding factors that change over time, such as increasing medication compliance, changes in the frequency of outpatient visit, or changes in personal interest in health. Finally, due to the limitation of our database, we cannot consider seasonal variation, which is one of the vital factors in pneumonia risk.

In conclusion, the use of all antihypertensives were associated with a reduced risk of pneumonia hospitalization in the general population of South Korea. Our results were consistent with that of the previous reports and further suggested that frequent medical service usage and protective immunity were primarily related to a reduced risk of pneumonia in the general population of South Korea.

ACKNOWLEDGMENTS

This work used the NHIS-NSC data compiled by the National Health Insurance Service as a database (NHIS-2021-2-196).

SUPPLEMENTARY MATERIALS

Supplementary Data 1
2019 Korean medication list published by the National Health Insurance Review and Assessment Service

Click here to view

Supplementary Table 1
Medication usage of participants

Click here to view

Supplementary Table 2
Sensitivity analysis

Click here to view
Supplementary Table 3
Entire results of logistic regression models in total patients and subgroups
Click here to view

Supplementary Table 4
Entire results of sensitivity analysis with all variables
Click here to view

REFERENCES

1. Buzzo AR, Roberts C, Mollinedo LG, Quevedo JM, Casas GL, Soldevilla JM. Morbidity and mortality of pneumonia in adults in six Latin American countries. Int J Infect Dis 2013;17(9):e673-7.
PUBMED | CROSSREF
2. Statistics Korea. 2020 cause of death statistics. http://kosis.kr. Updated 2021. Accessed February 24, 2022.
PUBMED | CROSSREF
3. Schmedt N, Heuer OD, Häckl D, Sato R, Theilacker C. Burden of community-acquired pneumonia, predisposing factors and health-care related costs in patients with cancer. BMC Health Serv Res 2019;19(1):30.
PUBMED | CROSSREF
4. Lim WS. Pneumonia—overview. In: Janes SM, editor. Encyclopedia of Respiratory Medicine. Amsterdam, Netherlands: Elsevier; 2022, 185-97.
PUBMED | CROSSREF
5. Huang KH, Kuo WY, Kuan YH, Chang YC, Tsai TH, Lee CY. Risk of pneumonia is associated with antipsychotic drug use among older patients with Parkinson’s disease: a case-control study. Int J Med Sci 2021;18(15):3565-73.
PUBMED | CROSSREF
6. Liapikou A, Cilloniz C, Torres A. Drugs that increase the risk of community-acquired pneumonia: a narrative review. Expert Opin Drug Saf 2018;17(10):991-1003.
PUBMED | CROSSREF
7. Restrepo MI, Mortensen EM, Anzueto A. Common medications that increase the risk for developing community-acquired pneumonia. Curr Opin Infect Dis 2010;23(2):145-51.
PUBMED | CROSSREF
8. van de Garde EM, Souverein PC, van den Bosch JM, Deneer VH, Leufkens HG. Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population. Eur Respir J 2006;27(6):1217-22.
PUBMED | CROSSREF
9. Liu CL, Shau WY, Wu CS, Lai MS. Angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers and pneumonia risk among stroke patients. J Hypertens 2012;30(11):2223-9.
PUBMED | CROSSREF
10. van de Garde EM, Souverein PC, Hak E, Deneer VH, van den Bosch JM, Leufkens HG. Angiotensin-converting enzyme inhibitor use and protection against pneumonia in patients with diabetes. J Hypertens 2007;25(1):235-9.
PUBMED | CROSSREF
11. Caldeira D, Alarcão J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ 2012;345:e4260.
PUBMED | CROSSREF
12. Yun JH, Rhee SY, Chun S, Kim HS, Oh BM. Association between antihypertensive use and hospitalized pneumonia in patients with stroke: a Korean nationwide population-based cohort study. J Korean Med Sci 2022;37(15):e112.
PUBMED | CROSSREF
13. Lee J, Lee JS, Park SH, Shin SA, Kim K. Cohort profile: the National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea. Int J Epidemiol 2017;46(2):e15.
PUBMED
14. Lee JS, Chui PY, Ma HM, Auyeung TW, Kng C, Law T, et al. Does low dose angiotensin converting enzyme inhibitor prevent pneumonia in older people with neurologic dysphagia—a randomized placebo-controlled trial. J Am Med Dir Assoc 2015;16(8):702-7.
PUBMED | CROSSREF
15. Ohkubo T, Chapman N, Neal B, Woodward M, Omae T, Chalmers J, et al. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. *Am J Respir Crit Care Med* 2004;169(9):1041-5. [PUBMED | CROSSREF]

16. Sekizawa K, Matsui T, Nakagawa T, Nakayama K, Sasaki H. ACE inhibitors and pneumonia. *Lancet* 1998;352(9133):1069. [PUBMED | CROSSREF]

17. Wang HC, Lin CC, Lau CI, Chang A, Kao CH. Angiotensin-converting enzyme inhibitors and bacterial pneumonia in patients with Parkinson disease. *Mov Disord* 2015;30(4):593-6. [PUBMED | CROSSREF]

18. Shinohara Y, Orihara H. Post-stroke pneumonia prevention by angiotensin-converting enzyme inhibitors: results of a meta-analysis of five studies in Asians. *Adv Ther* 2012;29(10):900-12. [PUBMED | CROSSREF]

19. Williams VR, Scholey JW. Angiotensin-converting enzyme 2 and renal disease. *Curr Opin Nephrol Hypertens* 2018;27(1):35-41. [PUBMED | CROSSREF]

20. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. *Physiol Rev* 2006;86(3):747-803. [PUBMED | CROSSREF]

21. Just PM. The positive association of cough with angiotensin-converting enzyme inhibitors. *Pharmacotherapy* 1989;9(2):82-7. [PUBMED | CROSSREF]

22. Tomaki M, Ichinose M, Miura M, Hirayama Y, Kageyama N, Yamauchi H, et al. Angiotensin converting enzyme (ACE) inhibitor-induced cough and substance P. *Thorax* 1996;51(2):199-201. [PUBMED | CROSSREF]

23. El Solh AA, Saliba R. Pharmacologic prevention of aspiration pneumonia: a systematic review. *Am J Geriatr Pharmacother* 2007;5(4):352-62. [PUBMED | CROSSREF]

24. Ikeda J, Kojima N, Saeki K, Ishihara M, Takayama M. Perindopril increases the swallowing reflex by inhibiting substance P degradation and tyrosine hydroxylase activation in a rat model of dysphagia. *Eur J Pharmacol* 2015;746:126-31. [PUBMED | CROSSREF]

25. Arai T, Yasuda Y, Takaya T, Toshima S, Kashiki Y, Yoshimi N, et al. ACE inhibitors and symptomless dysphagia. *Lancet* 1998;352(9122):115-6. [PUBMED | CROSSREF]

26. El-Hashim AZ, Amine SA. The role of substance P and bradykinin in the cough reflex and bronchoconstriction in guinea-pigs. *Eur J Pharmacol* 2005;513(1-2):125-33. [PUBMED | CROSSREF]

27. Nataraj C, Oliverio MI, Mannon RB, Mannon PJ, Audoly LP, Amuchastegui CS, et al. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. *J Clin Invest* 1999;104(12):1693-701. [PUBMED | CROSSREF]

28. Di Raimondo D, Tuttolomondo A, Buttà C, Miceli S, Licata G, Pinto A. Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation. *Curr Pharm Des* 2012;18(28):4385-413. [PUBMED | CROSSREF]

29. Shrikrishna D, Astin R, Kemp PR, Hopkinson NS. Renin-angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. *Clin Sci (Lond)* 2012;123(8):487-98. [PUBMED | CROSSREF]

30. Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA. Angiotensin-converting enzyme inhibitor use and pneumonia risk in community-dwelling older adults: results from a population-based case-control study. *Pharmacoepidemiol Drug Saf* 2012;21(11):1173-82. [PUBMED | CROSSREF]

31. Liu CL, Shau WY, Chang CH, Wu CS, Lai MS. Pneumonia risk and use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. *J Epidemiol* 2013;23(5):344-50. [PUBMED | CROSSREF]

32. Gillespie SH, Balakrishnan I. Pathogenesis of pneumococcal infection. *J Med Microbiol* 2000;49(12):1057-67. [PUBMED | CROSSREF]

33. DiBardino DM, Wunderink RG. Aspiration pneumonia: a review of modern trends. *J Crit Care* 2015;30(1):40-8. [PUBMED | CROSSREF]
34. Lansbury L, Lim B, McKeever TM, Lawrence H, Lim WS. Non-invasive pneumococcal pneumonia due to vaccine serotypes: a systematic review and meta-analysis. eClinicalMedicine 2022;44:101271.

PUBMED | CROSSREF

35. Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O'Brien KL, Andreo F, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One 2013;8(4):e60273.

PUBMED | CROSSREF

36. Imamura Y, Miyazaki T, Watanabe A, Tsukada H, Nagai H, Hasegawa Y, et al. Prospective multicenter survey for Nursing and Healthcare-associated Pneumonia in Japan. J Infect Chemother 2022;28(8):1125-30.

PUBMED | CROSSREF

37. Andersen CT, Langendorf C, Garba S, Sayinzonga-Makombe N, Mambula C, Mouniaman I, et al. Risk of community- and hospital-acquired bacteremia and profile of antibiotic resistance in children hospitalized with severe acute malnutrition in Niger. Int J Infect Dis 2022;119:163-71.

PUBMED | CROSSREF

38. Jaradeh S. Neurophysiology of swallowing in the aged. Dysphagia 1994;9(4):218-20.

PUBMED | CROSSREF

39. Tracy JF, Logemann JA, Kahrilas PI, Jacob P, Kobara M, Krugler C. Preliminary observations on the effects of age on oropharyngeal deglutition. Dysphagia 1989;4(2):90-4.

PUBMED | CROSSREF

40. Ren J, Shaker R, Kusano M, Podvrsan B, Metwally N, Dua KS, et al. Effect of aging on the secondary esophageal peristalsis: presbyesophagus revisited. Am J Physiol 1995;268(5 Pt 1):G772-9.

PUBMED

41. Nilsson H, Ekberg O, Olsson R, Hindfelt B. Quantitative aspects of swallowing in an elderly nondysphagic population. Dysphagia 1996;11(3):180-4.

PUBMED | CROSSREF

42. Benfield T, Jensen JS, Nordestgaard BG. Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome. Diabetologia 2007;50(3):549-54.

PUBMED | CROSSREF

43. Jensen AV, Faurholt-Jepsen D, Egelund GB, Andersen SB, Benfield T, et al. Undiagnosed diabetes mellitus in community-acquired pneumonia: a prospective cohort study. Clin Infect Dis 2017;65(12):2091-8.

PUBMED | CROSSREF

44. Pratt N, Roughhead EE, Ramsay E, Salter A, Ryan P. Risk of hospitalization for hip fracture and pneumonia associated with antipsychotic prescribing in the elderly: a self-controlled case-series analysis in an Australian health care claims database. Drug Saf 2011;34(7):567-75.

PUBMED | CROSSREF

45. Trifirò G, Gambassi G, Sen EF, Caputi AP, Bagnardi V, Brea J, et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. Ann Intern Med 2010;152(7):418-25.

PUBMED | CROSSREF

46. Herzig SJ, LaSalvia MT, Naidus E, Rothberg MB, Zhou W, Gurwitz JH, et al. Antipsychotics and the risk of aspiration pneumonia in individuals hospitalized for nonpsychiatric conditions: a cohort study. J Am Geriatr Soc 2017;65(12):2580-6.

PUBMED | CROSSREF